OverviewSuggest Edit

BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company. It develops immuno-oncology cancer therapies and offers a drug development pipeline which includes a variety of Plinabulin products. The company also provides a preclinical immuno-oncology pipeline that includes BPI-002, BPI-003, and BPI-004 programs.

TypePublic
Founded2010
HQNew York, NY, US
Websitebeyondspringpharma.com
Employee Ratings2.6

Latest Updates

Employees (est.) (Dec 2019)61(+18%)
Share Price (Jul 2021)$9.8(+6%)
Cybersecurity ratingCMore

Key People/Management at BeyondSpring

Lan Huang

Lan Huang

Co-Founder, Chairman & Chief Executive Officer
Patrick Fabbio

Patrick Fabbio

Director
Ramon Mohanlal

Ramon Mohanlal

EVP, Research and Development, Chief Medical Officer
Matthew Kirby

Matthew Kirby

Director
Rich Daly

Rich Daly

Chief Operating Officer
Ravindra Majeti

Ravindra Majeti

Director
Show more

BeyondSpring Office Locations

BeyondSpring has an office in New York
New York, NY, US (HQ)
28 Liberty St 39th Floor
Show all (1)

BeyondSpring Financials and Metrics

BeyondSpring Revenue

USD

Net income (FY, 2019)

(40.3m)

EBIT (FY, 2019)

(40.3m)

Market capitalization (28-Jul-2021)

381.3m

Closing stock price (28-Jul-2021)

9.8

Cash (31-Dec-2019)

35.9m

EV

349.3m
BeyondSpring's current market capitalization is $381.3 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

1.9m9.1m5.9m9.0m

R&D expense

10.4m88.9m51.6m31.3m

Operating expense total

12.4m98.0m57.5m40.3m

EBIT

(12.4m)(98.0m)57.5m(40.3m)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

General and administrative expense

1.0m2.8m3.3m728.0k1.4m1.5m1.6m2.1m2.5m

R&D expense

46.7m12.2m15.3m14.1m11.0m14.1m6.3m5.2m7.2m

Operating expense total

47.8m15.0m18.6m14.8m12.4m15.7m8.0m7.3m9.7m

EBIT

(47.8m)(15.0m)(18.6m)(14.8m)(12.4m)(15.7m)(7.7m)(7.3m)(9.7m)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

11.7m27.5m3.9m35.9m

Prepaid Expenses

360.0k264.0k292.0k410.0k

Current Assets

14.7m32.3m5.9m40.9m

PP&E

80.0k123.0k282.0k209.0k
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(12.5m)(96.4m)(57.5m)(40.3m)

Depreciation and Amortization

18.0k32.0k48.0k77.0k

Accounts Payable

144.0k2.9m6.2m(7.0m)

Cash From Operating Activities

(13.7m)(28.8m)(40.0m)(48.2m)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2019Q1, 2019Q2, 2019Q3, 2019

Net Income

47.7m(62.6m)(80.1m)(14.1m)(26.9m)(42.8m)(7.8m)(15.4m)(25.3m)

Depreciation and Amortization

6.0k13.0k22.0k12.0k20.0k29.0k23.0k41.0k61.0k

Accounts Payable

568.0k1.6m581.0k1.0m(575.0k)(18.0k)(620.0k)(1.1m)(7.6m)

Cash From Operating Activities

(5.3m)(10.4m)(18.6m)(8.9m)(22.0m)(31.6m)(5.1m)(13.1m)(35.5m)
USDFY, 2016

Financial Leverage

1.2 x
Show all financial metrics

BeyondSpring Operating Metrics

FY, 2016Feb, 2018Mar, 2019Mar, 2020

Patents

72727681

Patents (Plinabulin and Plinabulin Analogs, US)

13131616

Patents (US)

17172020

Patent Applications (US)

6101413
Show all operating metrics

BeyondSpring Acquisitions / Subsidiaries

Company NameDateDeal Size
Beijing Wanchun Pharmaceutical Technology Ltd.
BeyondSpring (HK) Limited
BeyondSpring LTD.
BeyondSpring Pharmaceuticals Inc.
BeyondSpring Pharmaceuticals Australia PTY 
SEED
SEED Technology
Wanchun Biotechnology Limited
Wanchun Biotechnology (Shenzhen) Ltd.
Wanchunbulin

BeyondSpring Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

SecurityScorecard logo

BeyondSpring Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

BeyondSpring Online and Social Media Presence

Embed Graph

BeyondSpring News and Updates

BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney

NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the appointment of Brendan Delaney to its Board of Directors, effective immediately. Mr. Del…

BeyondSpring to Participate in the William Blair Biotech Focus Conference

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will participate in the William Blair Biotech Focus Conference being held vir…

BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the develop…

BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update

- NDA Filed by U.S. Food and Drug Administration (FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of CIN. A PDUFA date of November 30, 2021 has been assigned by the FDA

BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial results for the first qua…
Show more

BeyondSpring Blogs

BeyondSpring’s Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced Neutropenia Presented at ASH 2019 Annual Meeting

Trial Aims to Optimize Chemotherapy by Minimizing Dose Modifications Due to Chemotherapy-Induced Neutropenia or Bone Pain NEW YORK , Dec. 10, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer

BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting

BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting Content Import Mon, 12/09/2019 - 08:01 BeyondSpring’s Abstracts on Clinical Evidence for Bone Marr…

BeyondSpring’s Single-Blinded Design (for Patients Only) of Phase 3 Study 103 (DUBLIN-3) Prevented Premature Patient Drop-Out: Data Accepted for Presentation at SITC 2019

Premature Patient Drop-Out Rate from Comparator Arm Might Contribute to Negative Trial Outcome, and was Avoided in DUBLIN-3 NEW YORK , Nov. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology

BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources

NEW YORK , Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has appointed Gregg Russo as Senior Vice President, Human Resources,

BeyondSpring Announces Pricing of Ordinary Shares

NEW YORK , Oct. 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the pricing of its

BeyondSpring Announces Proposed Public Offering of Ordinary Shares

NEW YORK , Oct. 24, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the launch of an
Show more

BeyondSpring Frequently Asked Questions

  • When was BeyondSpring founded?

    BeyondSpring was founded in 2010.

  • Who are BeyondSpring key executives?

    BeyondSpring's key executives are Lan Huang, Patrick Fabbio and Ramon Mohanlal.

  • How many employees does BeyondSpring have?

    BeyondSpring has 61 employees.

  • Who are BeyondSpring competitors?

    Competitors of BeyondSpring include Omeros, Athersys and Otonomy.

  • Where is BeyondSpring headquarters?

    BeyondSpring headquarters is located at 28 Liberty St 39th Floor, New York.

  • Where are BeyondSpring offices?

    BeyondSpring has an office in New York.

  • How many offices does BeyondSpring have?

    BeyondSpring has 1 office.